By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Dyax Corp. 

55 Network Drive

Burlington  Massachusetts  01803  U.S.A.
Phone: 617-225-2500 Fax: 617-225-2501


Founded in 1995, Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company’s key areas of focus are the KALBITOR® (ecallantide) business and the Angioedema Portfolio, as well as the Licensing and Funded Research Program (LFRP).

Dyax discovered and developed KALBITOR on its own and, since February 2010, the Company has been selling it in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Outside of the United States, the Company has established partnerships to obtain regulatory approval for and commercialize KALBITOR in certain markets and is evaluating opportunities in others. Currently, Dyax has collaboration agreements for regions including Europe, Japan, Russia, the Middle East, Australia and New Zealand. Dyax is also exploring other potential indications for KALBITOR, either alone or through collaborations.

The Company is expanding its portfolio for the treatment of angioedemas by identifying diagnostic strategies to assist in the differentiation between histamine-mediated and plasma kallikrein (bradykinin) mediated (PKM) angioedema, and developing a fully human monoclonal antibody inhibitor of plasma kallikrein, DX-2930, which could be a candidate to prophylactically treat PKM angioedemas.

KALBITOR and DX-2930 were identified using Dyax’s patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees, which currently includes 11 product candidates in various stages of clinical development, including three in Phase 3 trials.

Dyax is headquartered in Burlington, Massachusetts. For online information about Dyax Corp., please visit

Key Statistics

Ownership: Public

Web Site: Dyax
Employees: 120
Symbol: DYAX



CMIC Co., Ltd.  Ecallantide in HAE and other angioedemas indications

Sigma-Tau Group  Ecallantide in HAE and other therapeutic indications

Eli Lilly  Antibody phage display

Amgen  Antibody phage display

Merrimack  Antibody phage display

Sanofi-Aventis (New Jersey)  Antibody phage display

Biogen  Antibody phage display

Sanofi Genzyme  Hereditary Angioedema

Company News
Dyax (DYAX) Recognized As A “Top Place To Work” By The Boston Globe For Second Year In A Row 11/17/2015 10:33:22 AM
Dyax (DYAX) Presents Phase 1b DX-2930 Data At American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting 11/10/2015 12:26:34 PM
Shire (SHPG)'s New Buy Dyax (DYAX) is Another Biotech with Ties to Genzyme 11/3/2015 6:55:58 AM
Dyax (DYAX) Announces Cancellation Of Research And Development Day 11/2/2015 9:03:11 AM
Still Yearning for Baxalta (BXLT), Shire (SHPG) Snaps Up Dyax (DYAX) in $5.9 Billion Deal 11/2/2015 6:00:04 AM
Dyax Corp. (DYAX) Announces Third Quarter 2015 Financial Results 10/29/2015 11:00:36 AM
Dyax Corp. (DYAX) To Webcast 2015 Research And Development Day 10/27/2015 12:32:57 PM
Dyax Corp. (DYAX) To Review Third Quarter 2015 Financial Results At Research And Development Day 10/27/2015 10:24:51 AM
Dyax Corp. (DYAX) To Host Third Quarter 2015 Financial Results Call And Webcast 10/14/2015 4:10:17 PM
Dyax Corp. (DYAX) Receives Positive Opinion For Orphan Medicinal Product Designation In The European Union For DX-2930 For The Treatment Of Hereditary Angioedema 9/30/2015 11:50:56 AM